NCT01813500View on ClinicalTrials.gov

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

CompletedOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2015

Study Completion Date

April 30, 2016

Conditions
Crohn's DiseaseUlcerative ColitisClostridium DifficileInflammatory Bowel Disease
Interventions
OTHER

Blood and stool sample

Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors

Collaborators (1)

Cepheid
All Listed Sponsors
collaborator

Cepheid

INDUSTRY

collaborator

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

lead

Boston Medical Center

OTHER